Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Malignant hyperthermia


Other Names for this Disease

  • Anesthesia related hyperthermia
  • Fulminating hyperpyrexia
  • Hyperpyrexia malignant
  • Malignant hyperpyrexia
  • MH
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Management Guidelines

  • The European Malignant Hyperthermia Group has established guidelines for molecular genetic testing of malignant susceptibility and for in-vitro contracture testing. To read more, click on the link.
  • GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions. Click on the link to view the article on this topic.
  • Orphanet Emergency Guidelines is an article which is expert-authored and peer-reviewed that is intended to guide health care professionals in emergency situations involving this condition.  
  • Project OrphanAnesthesia is a project whose aim is to create peer-reviewed, readily accessible guidelines for patients with rare diseases and for the anesthesiologists caring for them. The project is a collaborative effort of the German Society of Anesthesiology and Intensive Care, Orphanet, the European Society of Pediatric Anesthesia, anesthetists and rare disease experts with the aim to contribute to patient safety.

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Malignant hyperthermia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name dantrolene sodium suspension for injection
Trade Name
(Manufacturer Name)
Ryanodex
(Eagle Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of malignant hyperthermia in conjunctin with appropriate supportive measures.
More Information about this product Drug Information Portal

Other Names for this Disease
  • Anesthesia related hyperthermia
  • Fulminating hyperpyrexia
  • Hyperpyrexia malignant
  • Malignant hyperpyrexia
  • MH
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.